uniQure N.V. (QURE)
After hours:
| Previous close | 18.70 |
| Open | 18.96 |
| Bid | 19.75 x 2200 |
| Ask | 21.11 x 800 |
| Day's range | 18.54 - 20.05 |
| 52-week range | 12.52 - 28.25 |
| Volume | |
| Avg. volume | 556,111 |
| Market cap | 933.961M |
| Beta (5Y monthly) | 1.07 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.81 |
| Earnings date | 01 May 2023 - 05 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 52.00 |
- GlobeNewswire
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 13, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the Company granted equity awards to 31 employees as a material inducement to commencing their employment. The equity awards were approved by the Company’s board of directors on February 23, 2023 (the “Grant Date”) in accordance with Nasdaq Listing Rule 5635(c
- Zacks
Are Options Traders Betting on a Big Move in UniQure (QURE) Stock?
Investors need to pay close attention to UniQure (QURE) stock based on the movements in the options market lately.
- GlobeNewswire
uniQure to Participate in Multiple Upcoming Industry Conferences in March
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 02, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and scientific conferences: Cowen Annual Healthcare Conference, March 6 – 8, 2023 Boston, MA Members of uniQure’s management team, including Matt Kapusta, chief executive officer, will participate in one-on-one i
